Last updated: March 13, 2026
What is the Product and Its Indication?
NDC 49348-0175 corresponds to Vaxneuvance (PCV20), a 20-valent pneumococcal conjugate vaccine developed by Merck. It is approved to prevent invasive pneumococcal disease (IPD) and pneumonia in adults aged 18 and older. Vaxneuvance entered the market as part of the expanding adult pneumococcal vaccination segment, competing primarily with Pfizer's Prevnar 13 (13-valent) and Pneumovax 23 (23-valent).
Market Position and Competitive Landscape
The pneumococcal vaccine market for adults has seen steady growth driven by aging populations and increased awareness of pneumococcal disease. Historically, Prevnar 13 held dominant market share, but the introduction of Vaxneuvance has expanded options and intensified competition.
Key competitors:
- Prevnar 13 (NDC 0078-0550)
- Pneumovax 23 (NDC 49281-031-01)
- Vaxneuvance (NDC 49348-0175)
Market size:
- The adult pneumococcal vaccine market in the U.S. was valued at approximately $1.2 billion in 2022.
- Projected CAGR (2023-2028): 4.5% (Source: IQVIA).
Adoption factors:
- Advisory Committee on Immunization Practices (ACIP) recommendations.
- Medicare and Medicaid reimbursement policies.
- Physician prescribing habits.
- Public awareness campaigns.
Price Analysis and Competitive Pricing Strategies
Current Wholesale Acquisition Cost (WAC):
- Vaxneuvance: Typically ranges between $150 and $180 per dose.
- Prevnar 13: Around $155.
- Pneumovax 23: Approximately $130 to $145.
Reimbursement and Insurance Impact:
- Actual patient out-of-pocket costs are often reduced through insurance and public programs.
- Medicare Part D covers pneumococcal vaccines, influencing pricing strategies.
Sector trends:
- Merck has employed a value-based pricing model, emphasizing the expanded serotype coverage.
- Price competition hinges on differentiation regarding indications and coverage scope.
Projected price trajectory:
- Will likely stabilize within the current range unless new competitors or formulations emerge.
- Minor downward pressure due to increased competition and payer negotiations is expected.
Future outlook:
- Pricing may see slight declines as market penetration increases and biosimilar or biosimilar-like products enter the market.
- Possible premium pricing depending on indications for high-risk populations or new approvals.
Regulatory and Policy Impact
- The CDC and ACIP inclusion of Vaxneuvance in adult vaccination schedules boosts market potential.
- Insurance coverage and government reimbursement policies will shape actual transaction prices.
- Market access strategies will influence overall revenue performance and price flexibility.
Market Entry and Expansion Opportunities
- Expand indications to pediatric or co-administration with other vaccines.
- Capitalize on emerging elderly populations and rising vaccine demands.
- Engage with public health agencies to secure statewide or nationwide procurement contracts.
Key Price Projections (2023-2028)
| Year |
Estimated WAC Range |
Notes |
| 2023 |
$150 - $180 |
Post-launch stabilization |
| 2024 |
$145 - $170 |
Slight price reduction due to market competition |
| 2025 |
$140 - $165 |
Further price adjustments with increased market penetration |
| 2026 |
$135 - $160 |
Potential introduction of competitive biosimilars |
| 2027 |
$130 - $155 |
Market maturation, stabilized pricing |
Risks to Market Share and Pricing
- Entry of generic or biosimilar competition.
- Changes in insurance coverage policies.
- Shifts in clinical guidelines favoring alternative vaccines.
- Public perception and vaccination uptake rates.
Final Remarks
Vaxneuvance’s market position remains robust due to its expanded serotype coverage. The current price range aligns with competitors, with potential for slight decreases driven by market dynamics. Continued adoption depends on payer strategies and regulatory policies.
Key Takeaways
- NDC 49348-0175 (Vaxneuvance) is a 20-valent pneumococcal vaccine targeting adult populations.
- Market size is approximately $1.2 billion annually, with steady growth.
- Current WAC: $150-$180 with pricing stability expected through 2028.
- Competitive pressures may induce minor price declines, especially if biosimilar options become available.
- Market growth depends heavily on insurer reimbursement policies and ACIP recommendations.
FAQs
-
How does Vaxneuvance compare to Prevnar 13 in terms of pricing?
Its WAC is similar, around $155, but Vaxneuvance offers broader serotype coverage, which may justify slight price differences.
-
What factors could impact the future pricing of Vaxneuvance?
Entry of biosimilars, payer negotiations, changes in clinical guidelines, and new regulatory approvals.
-
Will insurance coverage lead to lower out-of-pocket costs for patients?
Yes. Reimbursement rates influence actual patient costs, often making vaccines more accessible.
-
Are there plans to extend Vaxneuvance’s indications?
Merck may explore pediatric or co-administration uses, potentially expanding market reach.
-
What is the primary growth driver for this vaccine?
Aging populations and increasing awareness of pneumococcal disease in adults.
Sources
[1] IQVIA. (2023). US vaccine market report.
[2] CDC. (2022). Adult Immunization Schedule.
[3] Merck. (2022). Vaxneuvance product information.
[4] FDA. (2021). Approval of Vaxneuvance for adult pneumococcal disease prevention.
